Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

31
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
31
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Is clonal haematopoiesis the missing link between lupus and cardiovascular disease?

Rheumatology (Oxford, England)·2026
Same author

Myocarditis and the Role of Cardiac Imaging.

British journal of hospital medicine (London, England : 2005)·2026
Same author

Artificial intelligence methods to detect heart failure with preserved ejection fraction within electronic health records: an equitable disease detection model.

European heart journal. Digital health·2026
Same author

A "Hot" Cardiomyopathy.

The New England journal of medicine·2025
Same author

Inequity of access to contrast-enhanced cardiovascular magnetic resonance in patients with chronic kidney disease: A survey from the British Society of Cardiovascular Magnetic Resonance.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2025
Same author

Elevated Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Acute Myocarditis.

JACC. Heart failure·2025

関連する実験動画

Updated: Sep 9, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

慢性心不全の薬剤治療

Aamir Shamsi1, Daniel Sado2

  • 1King's College Hospital NHS Foundation Trust, London, UK aamir.shamsi@nhs.net.

Drug and therapeutics bulletin
|September 4, 2025
PubMed
まとめ
この要約は機械生成です。

このレビューは,エジェクション分数減少 (HFrEF) による慢性心不全の管理のための4つの主要な薬物クラスについて詳細に述べています. HFrEF患者における最適な結果は,早期診断とこれらの薬による個別化された治療に依存します.

キーワード:
心血管疾患薬物に関連した副作用と有害反応心不全主要な医療治療薬

さらに関連する動画

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K

関連する実験動画

Last Updated: Sep 9, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K

科学分野:

  • 心臓病科
  • 薬理学について
  • 内科 医学

背景:

  • 心不全 (HF) は,高い罹病率と死亡率を持つ進行症候群です.
  • HFは英国におけるNHSの緊急入院の5%を占め,医療資源に大きな影響を及ぼします.
  • 慢性心不全とエジェクション分数減少 (HFrEF) は,約60%のHF患者に影響します.

研究 の 目的:

  • 慢性HFrEFの薬理学的治療をレビューする.
  • HFrEF患者の管理における重要な考慮事項について議論する.
  • 薬の管理,合併症の対処,生活習慣の変更の重要性を強調する.

主な方法:

  • HFrEFの薬学的な治療戦略に重点を置く
  • 4つの主要な薬剤の分類:ACE阻害剤/ARNI,ベータブロッカー,MRA,SGLT2i.
  • これらの薬剤の相乗効果を強調する.

主要な成果:

  • HFrEF治療の4つの柱は,ACE阻害剤/ARNI,β阻害剤,MRA,およびSGLT2iである.
  • 個別化された治療と早期診断は 患者の治療結果にとって極めて重要です
  • これらの薬剤を併用した治療は,患者の治療結果を改善します.

結論:

  • 慢性HFrEFの効果的な管理は4つの主要な薬剤の組み合わせに依存しています.
  • パーソナライズされた治療計画には これらの薬が不可欠です
  • 総合的なケアには,薬の管理,合併症の対処,および改善されたHFrEFのアウトカムのためのライフスタイルの変更を促進します.